相似文献
1
Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer.
Clin Lung Cancer. 2017 Jan;18(1):e81-e83. doi: 10.1016/j.cllc.2016.10.001. Epub 2016 Oct 26.
2
Clinical Response to Everolimus of EGFR-Mutation-Positive NSCLC With Primary Resistance to EGFR TKIs.
Clin Lung Cancer. 2017 Jan;18(1):e85-e87. doi: 10.1016/j.cllc.2016.08.004. Epub 2016 Oct 4.
3
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Lung Cancer. 2015 Apr;88(1):74-9. doi: 10.1016/j.lungcan.2015.01.026. Epub 2015 Feb 7.
4
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.
5
Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.
Anticancer Drugs. 2016 Mar;27(3):251-3. doi: 10.1097/CAD.0000000000000317.
6
Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma.
Lung Cancer. 2014 Oct;86(1):102-4. doi: 10.1016/j.lungcan.2014.07.010. Epub 2014 Jul 24.
7
Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
Lung Cancer. 2012 Aug;77(2):464-8. doi: 10.1016/j.lungcan.2012.04.013. Epub 2012 May 12.
8
[A Case of Lung Adenocarcinoma Presenting with Leptomeningeal Carcinomatosis Successfully Treated with Afatinib after Erlotinib-Induced Hepatotoxicity].
Gan To Kagaku Ryoho. 2017 Jul;44(7):595-597.
9
Patient response to use of tyrosine kinase inhibitors in lung cancer: a retrospective audit during funding changes.
N Z Med J. 2017 Mar 3;130(1451):11-20.
10
Management Difficulties in a Patient with EGFR-mutation Positive Lung Adenocarcinoma and Cerebral Metastases.
Arch Bronconeumol. 2017 Jan;53(1):37-38. doi: 10.1016/j.arbres.2016.06.006. Epub 2016 Oct 3.
本文引用的文献
1
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
N Engl J Med. 2015 Apr 30;372(18):1689-99. doi: 10.1056/NEJMoa1411817.
2
Drug induced interstitial lung disease.
Open Respir Med J. 2012;6:63-74. doi: 10.2174/1874306401206010063. Epub 2012 Jul 27.
3
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.
4
Erlotinib achieved partial response in a non-small cell lung cancer patient with gefitinib-induced interstitial lung disease.
Case Rep Oncol. 2011 Sep;4(3):464-6. doi: 10.1159/000332195. Epub 2011 Sep 16.
5
Successful erlotinib rechallenge after erlotinib-induced interstitial lung disease.
J Thorac Oncol. 2011 Jun;6(6):1142-3. doi: 10.1097/JTO.0b013e318217b684.
6
Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia.
J Thorac Oncol. 2010 Jul;5(7):1105-6. doi: 10.1097/JTO.0b013e3181dc39cd.
7
Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease.
J Thorac Oncol. 2010 Jul;5(7):1103-4. doi: 10.1097/JTO.0b013e3181d89ac2.
8
Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease.
Cancer Chemother Pharmacol. 2010 Mar;65(4):803-6. doi: 10.1007/s00280-009-1212-5. Epub 2009 Dec 25.
9
Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.
Am J Respir Crit Care Med. 2007 Oct 15;176(8):814-8. doi: 10.1164/rccm.200705-715CR. Epub 2007 Jun 28.
10
Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
J Thorac Oncol. 2007 Jun;2(6):537-43. doi: 10.1097/JTO.0b013e318060d329.
Zotero 插件